Nuvectis Pharma, Inc. (NVCT) shareholders
NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$20.24+0.01 (+0.05%)
Close on Nov 13, 2026Market cap $659.45MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
31.5%
10M of 33M shares
Institutional holders
83
29 new, 6 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $1.17M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Charles Mosseri-Marlio | 2,595,000 | 15.00% | 13G (passive) amendment | Dec 31, 2023 |
| Levy Guy Joint filing with Soleus Capital Management, L.P. (5.10%), Soleus GP, LLC (5.10%) | 1,648,024 | 5.10% | 13G (passive) | Aug 4, 2026 |
| Enrique Poradosu | 1,503,819 | 8.70% | 13G (passive) amendment | Dec 31, 2023 |
| Shay Shemesh | 1,491,955 | 8.60% | 13G (passive) amendment | Dec 31, 2023 |
| Thomas Peters | 908,475 | 5.20% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NVCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 1,550,000 | 4.76% | $28.50M | New | 1.29% |
| BlackRock, Inc. | 1,001,285 | 3.07% | $18.41M | +236,844 | 0.00% |
| Perceptive Advisors LLC | 1,000,000 | 3.07% | $18.39M | New | 0.28% |
| Soleus Capital Management, L.P. | 1,000,000 | 3.07% | $18.39M | New | 0.63% |
| Vanguard Capital Management LLC | 872,482 | 2.68% | $16.04M | +212,603 | 0.00% |
| Iridian Asset Management LLC/Ct | 777,078 | 2.39% | $14.29M | +125,321 | 4.91% |
| Geode Capital Management, LLC | 432,273 | 1.33% | $7.95M | +48,168 | 0.00% |
| Sphera Funds Management Ltd. | 382,945 | 1.18% | $7.04M | New | 0.92% |
| Baldwin Brothers LLC/Ma | 382,015 | 1.17% | $7.03M | +3,390 | 0.46% |
| Occam Crest Management LP | 357,147 | 1.10% | $7.39M | −50,000 | 3.84% |
| Alyeska Investment Group, L.P. | 275,000 | 0.84% | $5.06M | New | 0.01% |
| State Street Corp | 248,198 | 0.76% | $4.56M | +81,682 | 0.00% |
| Susquehanna International Group, Llp | 217,286 | 0.67% | $4.00M | +112,000 | 0.00% |
| Avidity Partners Management LP | 200,000 | 0.61% | $3.68M | New | 0.59% |
| Kalehua Capital Management LLC | 200,000 | 0.61% | $3.68M | New | 1.17% |
| Northern Trust Corp | 146,714 | 0.45% | $2.70M | +22,502 | 0.00% |
| Vanguard Fiduciary Trust Co | 127,554 | 0.39% | $2.35M | +12,712 | 0.00% |
| Vanguard Portfolio Management LLC | 118,297 | 0.36% | $2.18M | +26,143 | 0.00% |
| Citadel Advisors LLC | 115,532 | 0.35% | $2.12M | +37,107 | 0.00% |
| Oppenheimer & Co Inc | 73,566 | 0.23% | $1.35M | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 83 | 10M | 31.5% | 29 / 34 | 11 / 6 | 6M | 0M |
| Q1 2026 | 62 | 4M | 13.8% | 17 / 20 | 9 / 1 | 1M | 0M |
| Q4 2025 | 48 | 4M | 13.0% | 3 / 25 | 9 / 8 | 1M | 0M |
| Q3 2025 | 53 | 4M | 11.4% | 11 / 14 | 14 / 5 | 1M | 0M |
| Q2 2025 | 47 | 3M | 10.0% | 22 / 15 | 6 / 8 | 2M | 0M |
| Q1 2025 | 33 | 2M | 6.3% | 10 / 13 | 3 / 8 | 1M | 0M |
| Q4 2024 | 31 | 1M | 4.1% | 7 / 14 | 8 / 7 | 0M | 0M |
| Q3 2024 | 31 | 1M | 3.2% | 4 / 9 | 11 / 13 | 0M | 0M |
| Q2 2024 | 41 | 1M | 3.7% | 17 / 10 | 12 / 16 | 0M | 1M |
| Q1 2024 | 40 | 2M | 5.1% | 6 / 16 | 11 / 2 | 0M | 0M |
| Q4 2023 | 36 | 2M | 4.7% | 5 / 17 | 6 / 2 | 0M | 0M |
| Q3 2023 | 33 | 1M | 3.9% | 1 / 14 | 13 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
72 funds held NVCT in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NVCT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 482,087 | 1.48% | $8.87M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 430,791 | 1.32% | $7.92M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 198,560 | 0.61% | $3.65M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 187,295 | 0.57% | $4.03M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 158,261 | 0.49% | $2.91M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 90,494 | 0.28% | $882.32K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 79,738 | 0.24% | $777.45K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 56,577 | 0.17% | $1.04M | 0.07% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 41,533 | 0.13% | $893.79K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 33,444 | 0.10% | $615.04K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 31,399 | 0.10% | $306.14K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 28,065 | 0.09% | $273.63K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 22,674 | 0.07% | $487.94K | 0.01% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 18,149 | 0.06% | $390.57K | 0.00% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 18,102 | 0.06% | $332.90K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ron Bentsur | Chairman & CEO, Director, 10% owner | 3,688,424 | 11.32% | Jul 1, 2026 |
| Michael J. Carson | Vice President, Finance | 230,118 | 0.71% | Aug 5, 2026 |
| Shay Shemesh | Chief Dev. & Ops. Officer | 1,793,068 | 5.50% | Jan 9, 2026 |
| Enrique Poradosu | Chief Science & Business Off | 1,806,319 | 5.54% | Jan 9, 2026 |
| Juan Sanchez | Director | 113,795 | 0.35% | Jun 12, 2026 |
| Kenneth Hoberman | Director | 168,140 | 0.52% | Jun 12, 2026 |
| James F. Oliviero III | Director | 122,828 | 0.38% | Jun 12, 2026 |
| Matthew L. Kaplan | Director | 159,760 | 0.49% | Jun 12, 2026 |
| Marlio Charles Mosseri | 10% owner | 3,295,897 | 10.12% | Jul 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael J. Carson Vice President, Finance | Aug 3, 2026 | Award | +30,000 | – | – | 230,118 |
| Marlio Charles Mosseri 10% owner | Jun 30, 2026 | Buy | +50,000 | $18.32 | $916.00K | 3,186,576 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Jun 30, 2026 | Buy | +12,500 | $20.00 | $250.00K | 3,688,424 |
| Kenneth Hoberman Director | Jun 11, 2026 | Award | +35,000 | – | – | 168,140 |
| Juan Sanchez Director | Jun 11, 2026 | Award | +35,000 | – | – | 113,380 |
| Matthew L. Kaplan Director | Jun 11, 2026 | Award | +35,000 | – | – | 159,760 |
| James F. Oliviero III Director | Jun 11, 2026 | Award | +35,000 | – | – | 122,828 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Jan 6, 2026 | Award | +150,000 | – | – | 3,675,924 |
| Michael J. Carson Vice President, Finance | Jan 6, 2026 | Award | +61,200 | – | – | 200,118 |
| Enrique Poradosu Chief Science & Business Off | Jan 6, 2026 | Award | +150,000 | – | – | 1,806,319 |
| Shay Shemesh Chief Dev. & Ops. Officer | Jan 6, 2026 | Award | +150,000 | – | – | 1,793,068 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Nov 5, 2025 | Buy | +5,000 | $5.72 | $28.60K | 3,525,924 |
| Juan Sanchez Director | Nov 5, 2025 | Buy | +13,000 | $5.79 | $75.27K | 78,150 |
| Matthew L. Kaplan Director | Nov 5, 2025 | Buy | +11,000 | $5.84 | $64.24K | 124,760 |
| Marlio Charles Mosseri 10% owner | Oct 27, 2025 | Buy | +72,836 | $6.28 | $457.41K | 3,136,576 |
| Marlio Charles Mosseri 10% owner | Oct 24, 2025 | Buy | +35,034 | $6.15 | $215.46K | 3,063,740 |
| Marlio Charles Mosseri 10% owner | Oct 23, 2025 | Buy | +46,900 | $6.06 | $284.21K | 3,028,706 |
| Juan Sanchez Director | Sep 22, 2025 | Award | +30,000 | – | – | 65,150 |
| Marlio Charles Mosseri 10% owner | Jun 20, 2025 | Buy | +5,603 | $7.99 | $44.77K | 2,981,806 |
| Marlio Charles Mosseri 10% owner | Jun 18, 2025 | Buy | +28,043 | $8.05 | $225.75K | 2,976,203 |
| Marlio Charles Mosseri 10% owner | Jun 17, 2025 | Buy | +5,399 | $8.11 | $43.79K | 2,948,160 |
| Matthew L. Kaplan Director | Jun 12, 2025 | Award | +30,000 | – | – | 113,760 |
| James F. Oliviero III Director | Jun 12, 2025 | Award | +30,000 | – | – | 87,828 |
| Kenneth Hoberman Director | Jun 12, 2025 | Award | +30,000 | – | – | 133,140 |
| Marlio Charles Mosseri 10% owner | May 12, 2025 | Buy | +21,167 | $8.11 | $171.66K | 2,942,761 |
| Marlio Charles Mosseri 10% owner | May 9, 2025 | Buy | +9,850 | $8.95 | $88.16K | 2,921,382 |
| Marlio Charles Mosseri 10% owner | May 9, 2025 | Buy | +9,817 | $8.90 | $87.37K | 2,931,199 |
| Marlio Charles Mosseri 10% owner | May 9, 2025 | Buy | +5,395 | $8.98 | $48.45K | 2,936,594 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +100 | $8.99 | $899 | 2,909,032 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +100 | $8.71 | $871 | 2,909,132 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +2,400 | $8.97 | $21.53K | 2,911,532 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +100 | $8.65 | $865 | 2,909,032 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +100 | $8.65 | $865 | 2,909,132 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +2,400 | $8.65 | $20.76K | 2,911,532 |
| Marlio Charles Mosseri 10% owner | May 8, 2025 | Buy | +50 | $8.65 | $433 | 2,908,932 |
| Marlio Charles Mosseri 10% owner | May 7, 2025 | Buy | +2,703 | $8.40 | $22.71K | 2,899,268 |
| Marlio Charles Mosseri 10% owner | May 7, 2025 | Buy | +9,614 | $8.64 | $83.06K | 2,908,882 |
| Marlio Charles Mosseri 10% owner | May 6, 2025 | Buy | +2,340 | $8.40 | $19.66K | 2,886,461 |
| Marlio Charles Mosseri 10% owner | May 6, 2025 | Buy | +10,104 | $8.64 | $87.30K | 2,896,565 |
| Marlio Charles Mosseri 10% owner | Feb 7, 2025 | Buy | +240,000 | $5.00 | $1.20M | 2,884,121 |
| Enrique Poradosu Chief Science & Business Off | Jan 2, 2025 | Award | +150,000 | – | – | 1,656,319 |
| Michael J. Carson Vice President, Finance | Jan 2, 2025 | Award | +51,000 | – | – | 138,918 |
| Shay Shemesh Chief Dev. & Ops. Officer | Jan 2, 2025 | Award | +150,000 | – | – | 1,643,068 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Jan 2, 2025 | Award | +250,000 | – | – | 3,520,924 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Dec 24, 2024 | Buy | +4,500 | $4.65 | $20.93K | 3,270,924 |
| Marlio Charles Mosseri 10% owner | Dec 13, 2024 | Buy | +17,000 | $4.70 | $79.90K | 2,612,000 |
| Marlio Charles Mosseri 10% owner | Dec 13, 2024 | Buy | +17,000 | $4.70 | $79.90K | 2,644,121 |
| Marlio Charles Mosseri 10% owner | Dec 12, 2024 | Buy | +32,121 | $4.64 | $149.04K | 2,627,121 |
| Enrique Poradosu Chief Science & Business Off | Nov 19, 2024 | Buy | +2,000 | $4.99 | $9.98K | 1,506,319 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Nov 15, 2024 | Buy | +20,000 | $4.92 | $98.40K | 3,266,424 |
| Michael J. Carson Vice President, Finance | Nov 7, 2024 | Sale | −2,755 | $8.16 | $22.48K | 87,918 |
| James F. Oliviero III Director | Jun 13, 2024 | Award | +30,000 | – | – | 57,828 |
| Matthew L. Kaplan Director | Jun 13, 2024 | Award | +30,000 | – | – | 83,760 |
| Kenneth Hoberman Director | Jun 13, 2024 | Award | +30,000 | – | – | 103,140 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | May 14, 2024 | Buy | +1,940 | $6.74 | $13.08K | 3,246,424 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | May 10, 2024 | Buy | +2,000 | $6.40 | $12.80K | 3,244,484 |
| Shay Shemesh Chief Dev. & Ops. Officer | May 10, 2024 | Buy | +1,113 | $6.32 | $7.03K | 1,493,068 |
| Enrique Poradosu Chief Science & Business Off | May 10, 2024 | Buy | +500 | $6.29 | $3.15K | 1,504,319 |
| Ron Bentsur Chairman & CEO, Director, 10% owner | Mar 18, 2024 | Buy | +5,000 | $10.29 | $51.45K | 3,242,484 |
| Michael J. Carson Vice President, Finance | Jan 4, 2024 | Award | +34,567 | – | – | 90,673 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
12.00%
3M shares short
Days to cover
15.2
At 0M shares a day
Change since last report
+6.0%
From 2M shares
Short volume, 20 days
63.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nuvectis Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,578 shares on Oct 5, 2026 over the last 90 days.
See a number that looks wrong?